Skip to content
Screener

EPS (Basic) at other companies

Schrodinger logo
SchrodingerSDGR
$0.08+114%
PVL
Palvella TherapeuticsPVLA
-$1.20-62.2%
Recursion Pharmaceuticals, Inc. logo
Recursion Pharmaceuticals, Inc.RXRX
-$0.25+39.0%
Celcuity logo
CelcuityCELC
-$0.97-12.8%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
-$3.06-134%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$2.42+868%

Other financials

Income statement

See full
Revenue$350.0K-48.3%
Operating income-$90.8M-18.2%
Net income-$83.7M-18.9%
EPS (diluted)-$0.410.0%

Balance sheet

See full
Cash & equivalents$121.2M+6.4%
Total debt$30.7M-10.3%
Total equity$890.0M+33.7%
Total assets$967.5M+32.7%

Cash flow

See full
Operating cash flow-$54.1M+2.1%
CapEx$1.0K
Free cash flow-$44.9M+22.5%

Valuation

See full
Market cap$4.3B+611%
Enterprise value$4.21B+702%
P/S415.9×+343×

Profitability

See full
Operating margin-2,999.4%-637pp
Net margin-2,763.6%-568pp
FCF margin-1,536%-429pp

Returns & leverage

See full
Return on equity-36.8%-6.3pp
Debt / equity0.0×
Current ratio18.3×-2.7×

Where this comes from

Reported directly by Relay Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.

The source filing: Relay Therapeutics, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:15 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-338056
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Other income (expense)2(633)(51)(641)
Total other income, net7,1176,47212,41614,277
Net loss$(83,707)$(70,375)$(156,998)$(147,440)
Net loss per share, basic and diluted$(0.41)$(0.41)$(0.82)$(0.87)
Weighted average shares of common stock, basic and diluted202,849,466171,264,622191,412,839170,254,500
Other comprehensive (loss) income:
Unrealized holding (loss) gain(1,381)(201)(2,286)828
Total other comprehensive (loss) income(1,381)(201)(2,286)828

Item 1. Financial Statements.

FAQ

What is Relay Therapeutics, Inc.'s EPS (basic)?
Relay Therapeutics, Inc. (RLAY) reported EPS (basic) of -$0.41 in Q2 2026.
How has Relay Therapeutics, Inc.'s EPS (basic) changed year-over-year?
Relay Therapeutics, Inc.'s EPS (basic) decreased by 0.0% year-over-year, from -$0.41 to -$0.41.
What is the long-term trend for Relay Therapeutics, Inc.'s EPS (basic)?
Over 4 years (2021 to 2025), Relay Therapeutics, Inc.'s EPS (basic) has grown at a -19.4% compound annual growth rate (CAGR), from -$3.82 to -$1.61.
What does EPS (basic) mean?
Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.

Ask your AI about Relay Therapeutics, Inc.'s eps (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude